5-Year Data for Vyxeos Liposomal: Perspectives From the United Kingdom (UK)

Watch as physicians from leading UK haematology centres share their thoughts on the 5-year results of Vyxeos Liposomal in Study 301, presented at the European Hematology Association (EHA) Virtual Congress 2020.1

Prescribing information can be found at the top of this page. Adverse event reporting is available at the bottom of this page.

Topics: Safety Vyxeos Liposomal Data


Adverse events should be reported. Reporting forms and information for the UK can be found at https://yellowcard.mhra.gov.uk/

For Ireland, reporting forms and information can be found at: www.hpra.ie

Adverse events should also be reported to Jazz Pharmaceuticals at AEreporting@jazzpharma.com

UK-VYX-2000171 | March 2021